A pilot study evaluated the safety and feasibility of CD8+ CAR-T cells targeting IL-13Rα2 in three recurrent GBM patients, and the results revealed a good safety profile and transient antitumor activity [59]. The gene discussed is CD8A; the disease is glioblastoma.